RCT on Intralesional Rituximab Injection Versus ISRT in Ocular Adnexal MALT Lymphoma

This study is comparing two treatments for a slow-growing lymphoma found in the tissues around the eye (ocular adnexal MALT lymphoma): a direct injection of rituximab (a targeted antibody) into the affected area versus targeted radiation therapy. **You may be eligible if...** - You are between 18 and 75 years old - You have been diagnosed with ocular adnexal MALT lymphoma (confirmed by biopsy) - Your disease is classified as early-to-intermediate stage (T1–T3 without deep orbital involvement) - You have not received any prior treatment specifically for this lymphoma **You may NOT be eligible if...** - Your lymphoma has spread deeply into the eye socket or is classified as T4 stage - You have a cataract that significantly affects vision or requires surgery - You need other eye surgery - You have certain other active eye conditions (corneal disease, glaucoma, etc.) Talk to your doctor to see if this trial is right for you.